Foot ulcers remain a common problem, leading to increased morbidity in patients with diabetes. Despite the progress that has been achieved in revascularization techniques as well as in off-loading to relieve high-pressure areas, diabetic foot wounds remain a clinical challenge. Growth factors are a major technological advance that promised to change the face of wound healing. The most important of growth factors are recombinant human platelet-derived growth factor-BB and granulocyte colony-stimulating factor. The former has been approved by the FDA for the treatment of neuropathic ulcers when there is adequate blood supply. The latter is less demonstrably useful. Advances include methods of delivering growth factors.
Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care2004;27:1047-1053.
2.
Coliaguri S, Borch-Johnsen K, Glümer C, et al. There really is an epidemic of type 2 diabetes. Diabetologia2005;48:1459-1463.
3.
Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted?J Intern Med2000;247:301-310.
4.
Gale EAM. Spring harvest? Reflections on the rise of type 1 diabetes. Diabetologia2005;48:2445-2450.
5.
Boulton AJM. The diabetic foot: from art to science. The 18th Camillo Golgi lecture. Diabetologia2004;47:1343-1353.
6.
Boulton AJM, Vileikyte L, Ragnarson-Tennvall G, et al. The global burden of diabetic foot disease. Lancet2005;366:1719-1724.
7.
Manes C, Papazoglou N, Sossidou E, et al. Prevalence of diabetic neuropathy and foot ulceration: identification of potential risk factors—a population-based study. Wounds2002;14:11-15.
8.
Papanas N, Maltezos E, Edmonds M. St. Vincent declaration after 15 years or who cleft the devil's foot?Vasa2006;35:3-4.
9.
Edmonds M. The diabetic foot, 2003. Diabetes Metab Res Rev2004;20(Suppl 1):S9-S12.
10.
Bakker K, Foster AVM, van Houtoum WH, Riley P, editors. International Diabetes Federation and International Working Group of the Diabetic Foot. Time to act. The Netherlands; 2005.
11.
Tentolouris N, Al-Sabbagh S, Walker MG, et al. Mortality in diabetic and nondiabetic patients after amputations performed from 1990 to 1995: a 5-year follow-up study. Diabetes Care2004;27:1598-1604.
12.
Reiber GE, Vileikyte L, Boyko EJ, et al. Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care1999;22:157-162.
13.
Edmonds ME, Foster AVM, Sanders LJ. Stage 3: the ulcerated foot. In: Edmonds ME, Foster AVM, Sanders LJ, editors. A practical manual of diabetic footcare. Oxford, UK: Blackwell; 2004. p. 62-101.
14.
Edmonds M, Foster A. Ulcer-free survival in diabetic foot patients. Diabet Med2005;22:1293-1294.
15.
Mantey I, Foster AV, Spencer S, et al. Why do foot ulcers recur in diabetic patients?Diabet Med1999;16:245-249.
16.
Margolis DJ, Allen-Taylor L, Hoffstad O, et al. Healing diabetic neuropathic foot ulcers: are we getting better?Diabet Med2005;22:172-176.
17.
Edmonds M, Bates M, Doxford M, et al. New treatments in ulcer healing and wound infection. Diabetes Metab Res Rev2000;16(Suppl 1):S51-S54.
18.
Jeffcoate W, Price P, Harding KG. Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev2004;20(Suppl 1):S78-S89.
19.
Kirsner RS, Bogensberger G. The normal process of healing. In: Kloth LC, McCulloch JM, editors. Wound healing alternatives in management. Philadelphia, Pa: FA Davis; 2002. p. 3-34.
20.
Falanga V. Wound healing and its impairment in the diabetic foot. Lancet2005;366:1736-1743.
21.
Singer AJ, Clark RA. Cutaneous wound healing. N Engl J Med1999;341:738-746.
22.
Kunimoto BT. Growth factors in wound healing: the next great innovation?Ostomy Wound Manage1999;45:56-64.
23.
Köveker GB. Growth factors in clinical practice. Int J Clin Pract2000;54:590-593.
24.
Boyce DE, Jones WD, Ruge F, et al. The role of lymphocytes in human wound healing. Br J Dermatol2000;143:59-65.
25.
Gillitzer R. Modern wound management. Hautarzt2002;53: 130-147.
26.
Ennis WJ, Meneses P. Factors impeding wound healing. In: Kloth LC, McCulloch JM, editors. Wound healing alternatives in management. Philadelphia, Pa: FA Davis; 2002. p. 68-96.
27.
Lewis B. Nutrition and wound healing. In: Kloth LC, McCulloch JM, editors. Wound healing alternatives in management. Philadelphia: FA Davis; 2002. p. 35-67.
28.
Lineaweaver W, McMorris S, Soucy D, et al. Cellular and bacterial toxicities of topical antimicrobials. Plast Reconstr Surg1985;75:394-396.
29.
Kucan JO, Robson MC, Heggers JP, et al. Comparison of silver sulfadiazine, povidone-iodine and physiologic saline in the treatment of chronic pressure ulcers. J Am Geriatr Soc1981;29:232-235.
30.
Brown CD, Zitelli JA. A review of topical agents for wounds and methods of wounding. J Dermatol Surg Oncol1993;19:732-737.
31.
Brown CD, Zitelli JA. Choice of wound dressings and ointments. Otolaryngol Clin North Am1995;28:1081-1091.
32.
Winter GD. Formation of the scab and the rate of epithelization of superficial wounds in the skin of the young domestic pig. Nature1962;193:293-294.
33.
Winter GD, Scales JT. Effect of air drying and dressings on the surface of a wound. Nature1963;197:91-92.
34.
Helfman T, Ovington L, Falanga V. Occlusive dressings and wound healing. Clin Dermatol1994;12:121-127.
35.
Lazarus GS, Cooper DM, Knighton DR, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol1994;130:489-493.
Límová M. New therapeutic options for chronic wounds. Dermatol Clin2002;20:357-363.
38.
Pfeffer F, von Dobschuetz E, Riediger H, et al. The non-healing wound. MMW Fortschr Med2004;146:45-48.
39.
American Diabetes Association. Consensus Development Conference on diabetic foot care. Diabetes Care1999;22:1354-1354.
40.
Sheehan P, Jones P, Caselli A, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care2003; 26: 1879-1882.
41.
Bennett SP, Griffiths GD, Schor AM, et al. Growth factors in the treatment of diabetic foot ulcers. Br J Surg2003;90:133-146.
42.
Cavanagh PR, Lipsky BA, Bradbury AW, et al. Treatment for diabetic foot ulcers. Lancet2005;366:1725-1735.
43.
Pecoraro R. Chronology and determination of tissue repair in diabetic lower extremity ulcers. Diabetes1991;40:1305-1313.
44.
Silhl N. Diabetes and wound healing. J Wound Care1998;7:47-51.
45.
Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA2005;293:217-228.
46.
Low PA. Sudomotor function. In: Gries FA, Low PA, Cameron NE, Ziegler D, editors. Textbook of diabetic neuropathy. Stuttgart: Georg Thieme Verlag; 2003. p. 274-278.
47.
Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med2004;351:48-55.
48.
Rayman G, Williams SA, Spencer PD, et al. Impaired microvascular hyperaemic response to minor skin trauma in type I diabetes. Br Med J (Clin Res Ed) 1986;292:1295-1298.
49.
Parkhouse N, Le Quesne PM. Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N Engl J Med1988;318:1306-1309.
50.
Duby JJ, Campbell RK, Setter SM, et al. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm2004;61:160-173.
51.
Edmonds ME, Foster AVM, Sanders LJ. Stage 4: the infected foot. In: Edmonds ME, Foster AVM, Sanders LJ, editors. A practical manual of diabetic footcare. Oxford (UK): Blackwell; 2004. p. 102-140.
52.
Lipsky BA. International consensus group on diagnosing and treating the infected diabetic foot. A report from the international consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev2004;20(Suppl 1):S68-S77.
53.
International Working Group of the Diabetic Foot. International Consensus on the Diabetic Foot. The Netherlands; 1999.
54.
Jude EB, Blakytny R, Bulmer J, et al. Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med2002;19:440-447.
55.
Black E, Vibe-Pedersen J, Jorgensen LN, et al. Decrease of collagen deposition in wound repair in type 1 diabetes independent of glycemic control. Arch Surg2003;138:34-40.
56.
Lepantalo M, Biancari F, Tukiainen E. Never amputate without consultation of a vascular surgeon. Diabetes Metab Res Rev2000; 16(Suppl 1):S27-S32.
57.
Andros G. Diagnostic and therapeutic arterial interventions in the ulcerated diabetic foot. Diabetes Metab Res Rev2000;20(Suppl 1):S29-S33.
58.
Adam DJ, Raptis S, Fitridge RA. Trends in the presentation and surgical management of the acute diabetic foot. Eur J Vasc Endovasc Surg2006;31:151-156.
59.
Sumpio BF, Lee T, Blume PA. Vascular evaluation and arterial reconstruction of the diabetic foot. Clin Podiatr Med Surg2003;20:689-708.
60.
Faries PL, Teodorescu VJ, Morrissey NJ, et al. The role of surgical revascularization in the management of diabetic foot wounds. Am J Surg2004;187(5A):34S-37S.
61.
Steed DL, Donohoe D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. Diabetic Ulcer Study Group. J Am Coll Surg1996;183:61-64.
62.
Piaggesi A, Schipani E, Campi F, et al. Conservative surgical approach versus non-surgical management for diabetic neuropathic foot ulcers: a randomized trial. Diabet Med1998;15:412-417.
63.
Shen JT, Falanga V. Innovative therapies in wound healing. J Cutan Med Surg2003;7:217-224.
64.
Greenhalgh DG. The role of growth factors in wound healing. J Trauma1996;41:159-167.
65.
Kiritsy CP, Lynch AB, Lynch SE. Role of growth factors in cutaneous wound healing: a review. Crit Rev Oral Biol Med1993;4:729-760.
66.
Lynch SE, Colvin RB, Antoniades HN. Growth factors in wound healing: single and synergistic effects on partial thickness porcine skin wounds. J Clin Invest1989;84:640-646.
67.
LeGrand EK, Senter LH, Gamelli RL, et al. Evaluation of PDGF-BB, PDGF-AA, bFGF, IL-1, and EGF dose responses in polyvinyl alcohol sponge implants assessed by a rapid histologic method. Growth Factors1993;8:315-329.
68.
Ross R, Glomset J, Kariya B, et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci U S A1974;71:1207-1210.
69.
Ganio C, Tenewitz FE, Wilson RC, et al. The treatment of chronic nonhealing wounds using autologous platelet-derived growth factors. J Foot Ankle Surg1993;2:63-68.
70.
Nagai MK, Embil JM. Becaplermin: recombinant platelet-derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol2002;2:211-218.
71.
Ross R. Platelet-derived growth factor. Lancet1989;1:1179-1182.
72.
Knighton DR, Ciresi KF, Fiegel VD, et al. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg1986;204:322-329.
73.
Doucette MD, Fylling C, Knighton DR. Amputation prevention in a high risk population through comprehensive wound-healing protocol. Arch Phys Med Rehabil1989;70:780-785.
74.
Knighton DR, Ciresi K, Fiegel VD, et al. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet1990;170:56-60.
75.
Meyer-Ingold W, Eichner W. Platelet-derived growth factor. Cell Biol Int1995;19:389-398.
76.
Piascik P. Use of Regranex gel for diabetic foot ulcers. J Am Pharm Assoc1998;38:628-630.
77.
LeGrand EK. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. Am J Surg1998;176(Suppl 2A):48S-54S.
78.
Robson MC, Philips LG, Thomason A, et al. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers. Lancet1992;339:23-25.
79.
Kallianinen LK, Hirshberg J, Marchant B, et al. Role of platelet-derived growth factor as an adjunct to surgery in the management of pressure ulcers. Plast Reconstr Surg2000;106:2343-2348.
80.
Stephens E, Robinson JA, Gottlieb PA. Becaplermin and necrobiosis lipoidicum diabeticorum: results of a case control pilot study. J Diabetes Complications2001;15:55-56.
81.
Shackelford DP, Fackler E, Hoffman MK, et al. Use of topical recombinant human platelet-derived growth factor BB in abdominal wound separation. Am J Obstet Gynecol2002;186:701-704.
82.
Hom DB, Manivel JC. Promoting healing with recombinant human platelet-derived growth factor-BB in a previously irradiated problem wound. Laryngoscope2003;113:1566-1571.
83.
Steed DL. Clinical evaluation of recombinant human platelet-derived growth factor for the treatment of lower extremity diabetic ulcers. J Vasc Surg1995;21:71-81.
84.
Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study. Diabetes Care1998;21:822-827.
85.
Wieman TJ. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Am J Surg1998;176(Suppl 2A):74S-79S.
86.
D'Hemercourt PA, Smiell JM, Karim MR. Effect of sodium carbomethylcellulose aqueous-based gel vs. becaplermin gel in patients with non-healing lower extremity diabetic ulcers. Wounds1998;10:69-75.
87.
Embil JM, Papp K, Sibblad G, et al. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of safety. Wound Rep Reg2000;8:162-168.
88.
Smiell JM. Clinical safety of becaplermin (rhPDGF-BB) gel. Am J Surg1998;176(Suppl 2A):68S-73S.
89.
Smiell JM, Wieman TJ, Steed DL, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Rep Reg1999;7:335-346.
90.
Ladin D and the Plastic Surgery Educational Foundation DATA Committee. Becaplermin gel (PDGF-BB) as topical wound therapy. Plast Reconstr Surg2000;105:1230-1231.
91.
Anonymous. Growth factor for diabetic foot ulcer. How many amputations are preventable?MMW Fortschr Med2000;142:60-60.
92.
Fruhstoffer B. Approval for recombinant growth factor. Since January 2000, patients with diabetic foot ulcers can be treated with the growth factor becaplermin (Regranex), manufactured by genetic technology. Internist2000;41:A38-A38.
93.
Watts SA. Platelet-derived growth factor for foot ulcerations. An effective adjunct to good wound acre. Adv Nurse Pract2001;9:60-63.
94.
Anonymous. Topical becaplermin. A slight short-term help for some diabetic patients. Rev Prescr2001;21:333-336.
95.
Margolis DJ, Bartus C, Hoffstad O, et al. Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers. Wound Rep Reg2005;13:531-536.
96.
Persson U, Willis M, Ödegaard K, et al. The cost-effectiveness of treating diabetic lower extremity ulcers with becaplermin (Regranex): a core model with an application using Swedish cost data. Val Health2000;3(Suppl I):S39-S46.
97.
Ghatnekar O, Persson U, Willis M, et al. Cost effectiveness of becaplermin in the treatment of diabetic foot ulcers in four European countries. Pharmacoeconomist2001;19:767-778.
98.
Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: a cost-effectiveness analysis. Dermatol Surg2001;27:347-351.
99.
Albert S. Cost-effective management of recalcitrant diabetic foot ulcers. Clin Podiatr Med Surg2002;19:483-491.
100.
Sibbald RG, Torrance G, Hux M, et al. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers. Ostomy Wound Manage2003;49:76-84.
101.
Miller SM. Use of topical recombinant human platelet-derived growth factor-BB (becaplermin) in healing of chronic mixed arteriovenous lower extremity diabetic ulcers. J Foot Ankle Surg1999;38:227-231.
102.
Boykin JV. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management. Adv Skin Wound Care2000;13:169-174.
103.
Niezgoda JA, van Gils CV, Frykberg RG, et al. Randomized clinical trial comparing OASIS wound matrix to Regranex gel for diabetic ulcers. Adv Skin Wound Care2005;18:258-266.
104.
Brown RL, Breeden MP, Greenhalgh DG. PDGF and TGF-αact synergistically to improve wound healing in the genetically diabetic mouse. J Surg Res1994;56:562-570.
105.
Castronuovo JJ, Ghobrial I, Giusti AM, et al. Effects of chronic wound fluid on the structure and biological activity of becaplermin (rhPDGF-BB) and becaplermin gel. Am J Surg1998;176(Suppl 2A):61S-67S.
106.
Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med1992;327:28-35.
107.
Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med1992;327:99-106.
108.
Martin-Christin F. Granulocyte colony stimulating factors: how different are they?Anticancer Drugs2001;12:185-191.
109.
Sylvester PK. Clinical applications of colony-stimulating factors: a historical perspective. Am J Health Syst Pharm2002;59:7(Suppl 2):S6-S12.
110.
Roilides E, Walsh TJ, Pizzo PA, et al. Granulocyte colony stimulating factor enhances the phagocytic and bactericidal activity of normal and defective neutrophils. J Infect Dis1991;163:579-583.
111.
Dale DC, Liles WC, Summer WR, et al. Granulocyte colony stimulating factor (GCSF): role and relationships in infectious diseasesJ Infect Dis1995;172:1061-1075.
112.
Marphoffer W, Stein M, Maeser E, et al. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care1992;15:256-260.
113.
Sato N, Shimizu H, Shimomura Y, et al. Myeloperoxidase activity and generation of active oxygen species in leukocytes from poorly controlled diabetic patients. Diabetes Care1992;15:1050-1052.
114.
Mason J, O'Keeffe C, Hutchinson A, et al. A systematic review of foot ulcer in patients with type 2 diabetes mellitus. II: treatment. Diabet Med1999;16:889-909.
115.
Cruciani M, Lipsky BA, Mengoli C, et al. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections?Diabetes Care2005;28:454-460.
116.
Gough A, Clapperton M, Rolando N, et al. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet1997;350:855-859.
117.
de Lalla F, Pellizzer G, Strazzabosco M, et al. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother2001;45:1094-1098.
118.
Yönem A, Cakir B, Guler S, et al. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab2001;3:322-337.
119.
Kreyden OP, Hafner J, Burg G, et al. Case report on therapy of with granylocyte stimulating factor in diabetic foot. Hautarzt2001;52:327-330.
120.
Baddour LM. Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Curr Infect Dis Rep2002;4:413-414.
121.
Kästenbauer T, Hornlein B, Sokol G, et al. Evaluation of granulocyte-colony stimulating factor (filgrastim) in infected diabetic foot ulcers. Diabetologia2003;46:427-430.
122.
Viswanathan V, Mahesh U, Jayaraman M, et al. Beneficial role of granulocyte colony stimulating factor in diabetic patients. J Assoc Physicians India2003;51:90-91.
123.
Reed KS, Pai MP. Adjunctive granulocyte colony-stimulating factor therapy for diabetic foot infections. Ann Pharmacother2004;38:2150-2153.
124.
Basile P, Rosenblum BI. Local care of the diabetic foot. In: Veves A, Giurini JM, Logerfo FW, editors. The diabetic foot: medical and surgical management. Totowa (NJ): Humana; 2002. p. 279-292.
125.
Chantelau E, Kimmerle R. Granulocyte-colony-stimulating factor in diabetic foot infection. Lancet1998;351:370-370.
126.
Cough A. Author's reply. Lancet1998;351:370-370.
127.
Peck KR, Son DW, Song JH, et al. Enhanced neutrophil functions by recombinant human granulocyte colony-stimulating factor in diabetic patients with foot infections in vitro. J Korean Med Sci2001;16:39-44.
128.
Huang P, Li S, Han M, et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care2005;28:2155-2160.
129.
Kawamura A, Horie T, Tsuda I, et al. Prevention of limb amputation in patients with limbs ulcers by autologous peripheral blood mononuclear cell implantation. Ther Apher Dial2005;9:59-63.
130.
Ashida A, Ohya Y, Sakuda H, et al. Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia. Circ J2005;69:1260-1265.
131.
Sasaki T. The effects of basic fibroblast growth factor and doxorubicin on cultured human skin fibroblasts: relevance to wound healing. J Dermatol1992;19:664-666.
132.
Quirinia A, Viidik A. The effect of recombinant basic fibrob-last growth factor (bFGF) in fibrin adhesive vehicle on the healing of ischaemic and normal incisional skin wounds. Scand J Plast Reconstr Hand Surg1998;32:9-18.
133.
Richard JL, Parer-Richard C, Daures JP, et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. Diabetes Care1995;18:64-69.
134.
Fu X, Shen Z, Guo Z, et al. Healing of chronic cutaneous wounds by topical treatment with basic fibroblast growth factor. Chin Med J2002;115:331-335.
135.
Brown GL, Curtsinger L, Brightwell JR, et al. Enhancement of epidermal regeneration by biosynthetic epidermal growth factor. J Exp Med1986;163:1319-1324.
136.
Brown GL, Curtsinger L, Jurkiewicz MJ, et al. Stimulation of healing of chronic wounds by epidermal growth factor. Plast Reconstr Surg1991;88:189-194.
137.
Tsang MW, Wong WKR, Hung CS, et al. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care2003;26:1856-1861.
138.
Generini S, Tuveri MA, Matucci Cerinic M, et al. Topical application of nerve growth factor in human diabetic foot ulcers. A study of three cases. Exp Clin Endocrinol Diabetes2004;112:542-544.
139.
Galiano RD, Tepper OM, Pelo CR, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol2004;164:1935-1947.
140.
Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Rep Reg2000;8:480-493.
141.
Slavin J, Hunt JA, Nash JR, et al. Recombinant basic fibrob-last growth factor in red blood cell ghosts accelerates incisional wound healing. Br J Surg1992;79:918-921.
142.
Elcin YM, Dixit V, Gitnick G. Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: implications for tissue engineering and wound healing. Artif Organs2001;25:558-565.
143.
Eming SA, Whitsitt JS, He L, et al. Particle-mediated gene transfer of PDGF isoforms promotes wound repair. J Invest Dermatol1999;112:297-302.
144.
Liechty KW, Nesbit M, Herlyn M, et al. Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischaemic impaired wound healing. J Invest Dermatol1999;113: 375-383.
145.
Breitbart AS, Laser J, Parrett B, et al. Accelerated diabetic wound healing using cultured dermal fibroblasts retrovirally transduced with the platelet-derived growth factor B gene. Ann Plast Surg2003;51:409-414.
146.
Man LX, Park JC, Terry MJ, et al. Lentiviral gene therapy with platelet-derived growth factor B sustains accelerated healing of diabetic wounds over time. Ann Plast Surg2005;55:81-86.
147.
Kawai K, Suzuki S, Tabata Y, et al. Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatine microspheres into artificial dermis. Biomaterials2000;21:489-499.
148.
Supp DM, Bell SM, Morgan JR, et al. Genetic modification of cultured skin substitutes by transduction of human keratinocytes and fibroblasts with platelet-derived growth factor-A. Wound Rep Reg2000;8:26-35.
149.
Isner JM, Pieczek A, Scainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of ph VEGF165 in a patient with ischaemic limb. Lancet1996;348:370-374.
150.
Lederman RJ, Mendelsohn FO, Anderson RD, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet2002;359:2053-2058.
151.
Ramachandran A. Specific problems of the diabetic foot in developing countries. Diabetes Metab Res Rev2004;20(Suppl 1):S19-S22.
152.
Margolis DJ, Kantor J, Santanna J, et al. Risk factors for delayed healing of neuropathic diabetic foot ulcers. Arch Dermatol2000;136:1531-1535.
153.
van Houtum W. Barriers to the delivery of diabetic foot care. Lancet2005;366:1678-1679.
154.
Papanas N, Maltezos E, Edmonds A, et al. The Ten Commandments of the diabetic foot. BMJ2005;331:1497-1497.
155.
Mills JL, Beckett WC, Taylor SM. The diabetic foot: consequences of delayed treatment and referral. South Med J1991;84:970-974.
156.
Bakker K, van Houtum WH, Riley PC. 2005: The International Diabetes Federation focus on the diabetic foot. Curr Diab Rep2005;5:436-440.
157.
Holstein P, Ellitsgaard N, Bornefeld Olsen B, et al. Decreasing incidence of major amputations in people with diabetes. VASA2001;58:28-31.
158.
van Houtum, Rauwerda JA, Ruwaard D, et al. Reduction in diabetes-related lower-extremity amputations in the Netherlands: 1991-2000. Diabetes Care2004;27:1042-1046.
